alexa Formation and persistence of DNA adducts in organs of CD-1 mice treated with a tumorigenic dose of fluoranthene.

Author(s): Wang JS, Busby WF Jr, Wogan GN

Abstract Share this page

Abstract Fluoranthene (FA) is tumorigenic to the lung when injected i.p. into CD-1 mice 1, 8 and 15 days after birth (Wang, J.-S. and Busby, W.F. Jr, Carcinogenesis, 14, 1871-1874, 1993). Levels, tissue distribution and persistence of FA--DNA adducts detected by HPLC-32P-postlabeling were investigated during the course of lung tumorigenesis by FA. Anti-10b-N2-deoxyguanosin-1,2,3,-trihydroxy-1,2,3 10b-tetrahydrofluoranthene [sequence: see text] (anti-FADE adduct) was consistently the major adduct in DNA samples from lung, heart, liver and kidney of animals examined at different time points from 2 h to 165 days after the last treatment with the tumorigenic dose (3.5 mg/mouse) of FA. Several unidentified adducts were also detected. Lung, the target organ for FA tumorigenicity, contained higher levels of anti-FADE adduct than other tissues from 1-165 days after treatment. The anti-FADE adduct level decreased in a biphasic manner after reaching maximum values at 2 h in heart and spleen plus thymus and 3 days in lungs, liver and kidneys. About 10\% of the maximum amount of anti-FADE adduct remained in lung, liver and heart 165 days after final FA treatment, at which time 44\% of animals had developed lung adenomas. Significant inter-litter variations, but no sex differences in adduct levels were observed. These results indicated a positive correlation between anti-FADE adduct level and persistence in relation to target organ specificity for tumor formation.
This article was published in Carcinogenesis and referenced in

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Recommended Journals

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords